KR19990022174A - 질소 산화물의 생체내 농도를 감소시키는 방법및 그에 유용한조성물 - Google Patents
질소 산화물의 생체내 농도를 감소시키는 방법및 그에 유용한조성물 Download PDFInfo
- Publication number
- KR19990022174A KR19990022174A KR1019970708653A KR19970708653A KR19990022174A KR 19990022174 A KR19990022174 A KR 19990022174A KR 1019970708653 A KR1019970708653 A KR 1019970708653A KR 19970708653 A KR19970708653 A KR 19970708653A KR 19990022174 A KR19990022174 A KR 19990022174A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- mgd
- alkyl
- dithiocarbamate
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/16—Salts of dithiocarbamic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
Description
조건 | [(MGD)2Fe-NO], μMa |
대조물 | 1.3 ± 0.2 (8)b |
+NMMA(50mg/kg) | 0.4 ± 0.3 (8)* |
+아세틸콜린(67mg/kg) | 3.9 ± 0.8 (3)* |
+덱사메타손(3mg/kg) | 1.4 ± 0.3 (7) |
a생쥐 뇨 중의 [(MGD)2Fe-NO] 착물 양은, 생쥐 뇨의 EPR 시그널 강도를 공지 농도의 [(MGD)2Fe-NO]를 포함하는 표준 용액의 시그널 강도와 비교하여 계산하였다.b제시된 데이터는 평균 ± 표준편차 (쥐의 수)이다.*대조물과 비교하여 P0.05 |
조건 | [(MGD)2Fe-NO], μMa |
LPS-처리됨b | |
0 시간 | 1.4 ± 0.4 (3)c |
2 시간 | 7.3 ± 2.2 (3)* |
4 시간 | 18.2 ± 4.8 (4)* |
6 시간 | 17.1 ± 4.8 (4)* |
8 시간 | 35.1 ± 5.7 (3)* |
LPS-처리됨(6시간 후)d | |
+NMMA(50mg/kg) | 3.6 ± 0.9 (4)+ |
+NMMA(100mg/kg) | 3.8 ± 2.3 (3)+ |
a생쥐 뇨 중의 [(MGD)2Fe-NO] 착물 양은 표 1에 기재한 바와 같이 결정하였다.b지시되는 바와 같이 LPS 투여한 후 다른 시점에서, [(MGD)2/Fe]을 쥐에 피하 주사하고,2시간 후 쥐를 희생시켜서 EPR 측정을 위한 뇨를 수집하였다.c제시된 데이터는 평균 ± 표준편차 (쥐의 수)이다.d[(MGD)2/Fe]을 주사하기 직전에 LPS 투여하고 6시간 후 각종 양의 NMMA을 복강내주사하였다. 2시간 후 뇨를 수집하였다.*대조물과 비교하여 P0.05 (표 1 참조)+6시간 동안 LPS-처리된 군과 비교하여 P0.05 |
조건 | 질산염/아질산염, μMa |
대조용 | 73 ± 7 (10)d |
LPS-처리됨b | |
2 시간 | 103 ± 10 (6)* |
4 시간 | 291 ± 38 (6)* |
6 시간 | 506 ± 75 (4)* |
8 시간 | 638 ± 29 (8)* |
LPS+[(MGD)2/Fe] 착물c | |
8시간 | 336 ± 46 (3)*+ |
a생쥐 플라즈마 내의 질산염/아질산염 결정을 상기한 바와 같이 수행하였다(상기[Komaro and Lai] 참조).bLPS를 정맥내 투여한 후 지시된 바와 같이 다른 시점에서 쥐를 희생시켰다.cLPS를 투여하고 6시간 경과후 [(MGD)2/Fe]을 피하 주사하고 2시간 후 희생시켰다d제시된 데이터는 평균 ± 표준편차 (쥐의 수)이다.*대조물과 비교하여 P0.05+8시간 동안 LPS-처리된 군과 비교하여 P0.05 |
조건1 | 바탕선2(평균±SEM) | LPS처리하고 2시간 후 | 처리하고 1.5 시간 후 |
a) 대조 염수(n=16)3 | 96±2 | 77±2 | 78±4 |
b) [(MGD)2/Fe](2/0.4)4(n=16) | 95±3 | 75±2 | 96±3 |
c) [(MGD)2/Fe](2/0.2)(n=6) | 98±3 | 73±4 | 87±4 |
d) MGD (2/0)(n=6) | 102±5 | 73±2 | 94±6 |
1실험 조건은 본원에 기재된 바와 같았다.2LPS 처리전 MAP 수치3n, 각 군에서 동물의 수4[(MGD)2/Fe] (2/0.4)는 [(MGD)2/Fe]의 비가 2 : 0.4인 것으로 정의된다. |
Claims (27)
- 치료 대상에게 유효량의 1종 이상의 디티오카르바메이트 함유 질소 산화물 스캐빈저를 투여하는 것을 포함하는, 치료 대상의 질소 산화물의 생체내 농도를 감소시키는 방법.
- 치료 대상에게 유효량의 1종 이상의 디티오카르바메이트 함유 질소 산화물 스캐빈저를 투여하는 것을 포함하는, 치료 대상의 질소 산화물 과생성을 치료하는 방법.
- 제2항에 있어서, 상기 질소 산화물 과생성이 패혈증 쇼크, 국소 빈혈, 사이토킨(cytokine)의 투여, 사이토킨의 과발현, 궤양, 궤양성 대장염, 당뇨병, 관절염, 천식, 알츠하이머(Alzheimer) 병, 파킨슨(Parkinson) 병, 다중 경화증, 경화증, 타가이식 거부증, 뇌척수염, 수막염, 췌장염, 복막염, 맥관염, 임파구 맥락수막염, 사구체신염, 포도막염, 회장염, 간 염증, 신장 염증, 출혈성 쇼크, 아나필락틱 쇼크, 화상, 크론(Crohn) 병, 감염, 혈액투석증, 만성 피로 증후군, 발작, 암, 심폐 혈관이식 또는 국소 빈혈/재환류 질환과 관련된 것인 방법.
- 제2항에 있어서, 상기 질소 산화물 과생성이 패혈증 쇼크, 국소 빈혈, IL-1의 투여, IL-2의 투여, IL-6의 투여, IL-12의 투여, 종양 괴사 인자의 투여, 인터페론-감마의 투여, 궤양, 궤양성 대장염, 당뇨병, 관절염, 천식, 알츠하이머병, 파킨슨병, 다중 경화증, 경화증 또는 타가이식 거부증과 관련된 것인 방법.
- 제2항에 있어서, 상기 질소 산화물 과생성이 패혈증 쇼크와 관련된 것인 방법.
- 제2항에 있어서, 상기 질소 산화물 과생성이 사이토킨 요법과 관련된 것인 방법.
- 제2항에 있어서, 상기 디티오카르바메이트 함유 질소 산화물 스캐빈저가 생리학적으로 적합한 2가 또는 3가 전이 금속 이온 및 하기 화학식의 디티오카르바메이트 잔기를 포함하는 것인 방법.R1R2N-C(S)-S-식 중,R1 및 R2는 각각 독립적으로 C1-C18알킬, 치환된 알킬, 시클로알킬, 치환된 시클로알킬, 헤테로시클릭, 치환된 헤테로시클릭, 알케닐, 치환된 알케닐, 알키닐, 치환된 알키닐, 아릴, 치환된 아릴, 헤테로아릴, 치환된 헤테로아릴, 알킬아릴, 치환된 알킬아릴, 아릴알킬, 치환된 아릴알킬로부터 선택되거나, 또는 R1 및 R2는 함께 결합하여 N, R1 및 R2를 포함하는 5-, 6- 또는 7-원 고리를 형성할 수 있다.
- 제7항에 있어서, 디티오카르바메이트 잔기에 대한 전이 금속의 비가 0 내지 약 1:2의 범위인 방법.
- 제7항에 있어서, 상기 생리학적으로 적합한 2가 또는 3가 전이 금속이 철, 코발트, 구리 또는 망간으로부터 선택되는 것인 방법.
- 제2항에 있어서, 상기 디티오카르바메이트 함유 질소 산화물 스캐빈저를 사이토킨, 항생제, 혈관 작용제, 또는 그의 혼합물과 함께 투여하는 방법.
- 제10항에 있어서, 상기 사이토킨이 IL-1, IL-2, IL-6, IL-12, TNF 또는 인터페론-γ로부터 선택되는 것인 방법.
- 제10항에 있어서, 상기 혈관 작용제가 카테콜라민, 노르아드레날린, 도파민 또는 도부타민으로부터 선택되는 것인 방법.
- 제2항에 있어서, 상기 디티오카르바메이트 함유 질소 산화물 스캐빈저가 경구, 정맥내, 피하, 비경구, 직장내 또는 흡입식으로 전달되는 방법.
- 제2항에 있어서, 상기 디티오카르바메이트 함유 질소 산화물 스캐빈저가 고형제, 용액제, 유제, 분산제, 미셀 또는 리포좀의 형태로 전달되는 방법.
- 하기 화학식 I의 화합물.화학식 IR1R2N-C(S)-S-M+식 중,R1 및 R2는 각각 독립적으로 C1-C18알킬, 치환된 알킬, 시클로알킬, 치환된 시클로알킬, 헤테로시클릭, 치환된 헤테로시클릭, 알케닐, 치환된 알케닐, 알키닐, 치환된 알키닐, 아릴, 치환된 아릴, 헤테로아릴, 치환된 헤테로아릴, 알킬아릴, 치환된 알킬아릴, 아릴알킬, 치환된 아릴알킬로부터 선택되거나, 또는 R1 및 R2는 함께 결합하여 N, R1 및 R2를 포함하는 5-, 6- 또는 7-원 고리를 형성할 수 있고,M은 1가 양이온이며,단, R1이 에틸이고, R2가 에틸이 아니거나; 또는 R1이 CH2(CHOH)4CH2OH이고, R2가 메틸, 이소아밀, 벤질, 4-메틸벤질 또는 p-이소프로필벤질이 아니거나; 또는 R1이 CH2CO2 -이고, R2가 CH2CO2 -가 아니거나; 또는 R1이 CO2 -이고, R2가 CH3가 아니거나; 또는 R1이 CH2CH2-OH이고, R2가 CH2CH2-OH가 아니거나; 또는 R1 및 R2가 카르바메이트 질소와 결합하여 피롤리디닐-2-카르복실레이트를 형성하는 화합물은 화학식 I의 정의에서 제외된다.
- 제15항에 있어서, M+이 H+, Na+, NH4 +또는 테트라알킬 암모늄으로부터 선택되는 것인 화합물.
- 하기 화학식 II의 화합물.화학식 II[R1R2N-C(S)-S-]2M+2, +3식 중,R1 및 R2는 각각 독립적으로 C1-C18알킬, 치환된 알킬, 시클로알킬, 치환된 시클로알킬, 헤테로시클릭, 치환된 헤테로시클릭, 알케닐, 치환된 알케닐, 알키닐, 치환된 알키닐, 아릴, 치환된 아릴, 헤테로아릴, 치환된 헤테로아릴, 알킬아릴, 치환된 알킬아릴, 아릴알킬, 치환된 아릴알킬로부터 선택되거나, 또는 R1 및 R2는 함께 결합하여 N, R1 및 R2를 포함하는 5-, 6- 또는 7-원 고리를 형성할 수 있고,M은 생리학적으로 적합한 2가 또는 3가 전이 금속 양이온이며,단, R1이 에틸이고, R2가 에틸이 아니거나; 또는 R1이 CH2(CHOH)4CH2OH이고, R2가 메틸, 이소아밀, 벤질, 4-메틸벤질 또는 p-이소프로필벤질이 아니거나; 또는 R1이 CH2CO2 -이고, R2가 CH2CO2 -가 아니거나; 또는 R1이 CO2 -이고, R2가 CH3가 아니거나; R1이 CH2CH2-OH이고, R2이 CH2CH2-OH가 아니거나; 또는 R1 및 R2가 카르바메이트 질소와 결합하여 피롤리디닐-2-카르복실레이트를 형성하는 화합물은 화학식 II의 정의에서 제외된다.
- 제17항에 있어서, 디티오카르바메이트 잔기에 대한 전이 금속의 비가 0 내지 약 1:2의 범위인 화합물.
- 제17항에 있어서, M이 Fe+2, Fe+3, Co+2, Co+3, Cu+2, Mn+2또는 Mn+3로부터 선택되는 것인 화합물.
- 제17항에 있어서,R1및 R2가 C1-C12알킬, 치환된 알킬, 알케닐, 치환된 알케닐, 알키닐 또는 치환된 알키닐이고, 여기서 치환기는 카르복실, -C(O)H, 옥시아실, 페놀, 페녹시, 피리디닐, 피롤리디닐, 아미노, 아미도, 히드록시, 니트로 또는 술푸릴로부터 선택되며,M이 Fe+2또는 Fe+3인 화합물.
- 제17항에 있어서,R1이 C2-C8알킬 또는 치환된 알킬이고, 여기서 치환기는 카르복실, 아세틸, 피리디닐, 피롤리디닐, 아미노, 아미도, 히드록시 또는 니트로로부터 선택되며,R2가 C1-C6알킬 또는 치환된 알킬로부터 선택되거나, 또는 R2가 R1와 함께 결합하여 N, R2및 R1을 포함하는 5-, 6- 또는 7-원 환을 형성할 수 있고,M이 Fe+2인 화합물.
- 제17항에 있어서,R1이 C2-C8알킬 또는 치환된 알킬이고, 여기서 치환기는 카르복실, 아세틸, 아미도 또는 히드록시로부터 선택되며,R2가 C1-C4알킬 또는 치환된 알킬이고,M이 Fe+2인 화합물이다.
- 제약상 허용되는 담체 중에 제17항의 화합물을 포함하는 조성물.
- 제23항에 있어서, 상기 제약상 허용되는 담체가 고형제, 용액제, 유제, 분산제, 미셀 또는 리포좀으로부터 선택되는 것인 조성물.
- 제23항에 있어서, 장용피를 추가로 포함하는 조성물.
- 제17항에 있어서, 약학적으로 활성인 작용제와 함께 제17항의 화합물을 포함하는 조성물.
- 제26항에 있어서, 상기 약학적으로 활성인 작용제가 사이토킨, 항생제, 혈관작용제, 또는 그의 혼합물로부터 선택되는 것인 조성물.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8/459518 | 1995-06-02 | ||
US08/459,518 US5756540A (en) | 1995-06-02 | 1995-06-02 | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US08/554,196 US5741815A (en) | 1995-06-02 | 1995-11-06 | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US8/554196 | 1995-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR19990022174A true KR19990022174A (ko) | 1999-03-25 |
Family
ID=27039393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970708653A KR19990022174A (ko) | 1995-06-02 | 1996-02-27 | 질소 산화물의 생체내 농도를 감소시키는 방법및 그에 유용한조성물 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5741815A (ko) |
EP (1) | EP0850240A4 (ko) |
JP (1) | JP3393606B2 (ko) |
KR (1) | KR19990022174A (ko) |
CN (1) | CN1075816C (ko) |
AU (1) | AU703952B2 (ko) |
CA (1) | CA2223276A1 (ko) |
WO (1) | WO1996038457A1 (ko) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6469057B1 (en) * | 1995-06-02 | 2002-10-22 | Mcw Research Foundation, Inc. | Methods for in vivo reduction of free radical levels and compositions useful therefor |
US5747532A (en) * | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
US5922761A (en) * | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
US6160021A (en) * | 1997-02-04 | 2000-12-12 | The General Hospital Corporation | Method for treating epidermal or dermal conditions |
US5858402A (en) * | 1997-02-11 | 1999-01-12 | Medinox, Inc. | Methods for in vivo reduction of cyanide levels and compositions useful therefor |
US6596770B2 (en) * | 2000-05-05 | 2003-07-22 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
US6265420B1 (en) * | 1998-06-23 | 2001-07-24 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
US6124349A (en) * | 1999-02-18 | 2000-09-26 | Medinox, Inc. | Method for preparation of pharmaceutical-grade dithiocarbamate |
US6274627B1 (en) * | 1999-10-12 | 2001-08-14 | Medinox, Inc. | Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor |
US6231894B1 (en) | 1999-10-21 | 2001-05-15 | Duke University | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2405709A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030143191A1 (en) * | 2001-05-25 | 2003-07-31 | Adam Bell | Chemokine beta-1 fusion proteins |
EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
CA2471363C (en) * | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1525003A1 (en) * | 2002-06-28 | 2005-04-27 | Pharmacia Corporation | Methods and contrast agents useful in quantifying nitric oxide |
US20060142621A1 (en) * | 2003-01-29 | 2006-06-29 | Tiekink Edward R T | Bismuth dithiocarbamate compounds and uses thereof |
US20060235370A1 (en) * | 2005-04-04 | 2006-10-19 | Oblong John E | Method of regulating mammalian keratinous tissue |
WO2006125324A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
EP2020998A4 (en) * | 2006-05-23 | 2010-07-21 | Univ Utah Res Found | COMPOSITIONS AND METHODS OF INHIBITING THE ENDOTHELIAL STAIN OXIDE SYNTHASE ACTIVITY |
US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20090112197A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
US20110190604A1 (en) * | 2006-12-22 | 2011-08-04 | Hyde Roderick A | Nitric oxide sensors and systems |
US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US8877508B2 (en) * | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
US10080823B2 (en) * | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
US8685728B2 (en) | 2008-01-31 | 2014-04-01 | Rutgers The State University Of New Jersey | Kit containing stem cells and cytokines for use in attenuating immune responses |
US10046011B2 (en) | 2008-01-31 | 2018-08-14 | Rutgers, The State University Of New Jersey | Compositions for inducing or suppressing an immune response |
WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用 |
US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
GB201117051D0 (en) * | 2011-10-04 | 2011-11-16 | Uni I Oslo | Carbonic anhydrase inhibitors |
US20140350097A1 (en) * | 2013-05-23 | 2014-11-27 | Medinox,Inc. | Treatment of hypotension associated with hemodialysis |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1863572A (en) * | 1926-12-18 | 1932-06-21 | Ig Farbenindustrie Ag | N-substituted dithiocarbamic acids and the salts thereof |
US2876159A (en) * | 1957-04-12 | 1959-03-03 | Sunderman Frederick William | Dithiocarbamates for treatment of nickel poisoning |
BE573077A (ko) * | 1957-11-18 | |||
US4166866A (en) * | 1975-05-21 | 1979-09-04 | The California Polytechnic State University Foundation | Immunosuppressive method with dithiocarbamates |
US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
JPS54126734A (en) * | 1978-03-24 | 1979-10-02 | Mamoru Morioka | Skin disease treating agent of human |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4554108A (en) * | 1983-07-26 | 1985-11-19 | Phillips Petroleum Company | Alkali carboxyalkyl dithiocarbamates and use as ore flotation reagents |
ATE26568T1 (de) * | 1983-09-30 | 1987-05-15 | Hydrel Ag | Verfahren zum aufwinden eines fadens zu einer spule und elektrohydraulische changiereinrichtung zur ausfuehrung des verfahrens. |
US4595538A (en) * | 1985-03-04 | 1986-06-17 | Phillips Petroleum Company | Tri-alkali metal-di(carboxyalkyl)dithiocarbamate and triammonium-di(carboxyalkyl)dithiocarbamate flotation agents |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5358703A (en) * | 1993-09-27 | 1994-10-25 | Mcw Research Foundation, Inc. | Method for the detection of nitric oxide |
-
1995
- 1995-11-06 US US08/554,196 patent/US5741815A/en not_active Expired - Fee Related
-
1996
- 1996-02-27 JP JP53643096A patent/JP3393606B2/ja not_active Expired - Fee Related
- 1996-02-27 EP EP96905577A patent/EP0850240A4/en not_active Ceased
- 1996-02-27 WO PCT/US1996/002605 patent/WO1996038457A1/en not_active Application Discontinuation
- 1996-02-27 KR KR1019970708653A patent/KR19990022174A/ko not_active IP Right Cessation
- 1996-02-27 CA CA002223276A patent/CA2223276A1/en not_active Abandoned
- 1996-02-27 CN CN96194392A patent/CN1075816C/zh not_active Expired - Lifetime
- 1996-02-27 AU AU49303/96A patent/AU703952B2/en not_active Expired
- 1996-12-09 US US08/767,125 patent/US5847004A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1186495A (zh) | 1998-07-01 |
EP0850240A4 (en) | 2001-08-29 |
US5847004A (en) | 1998-12-08 |
WO1996038457A1 (en) | 1996-12-05 |
AU4930396A (en) | 1996-12-18 |
EP0850240A1 (en) | 1998-07-01 |
JP3393606B2 (ja) | 2003-04-07 |
JPH11510789A (ja) | 1999-09-21 |
AU703952B2 (en) | 1999-04-01 |
CN1075816C (zh) | 2001-12-05 |
US5741815A (en) | 1998-04-21 |
CA2223276A1 (en) | 1996-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR19990022174A (ko) | 질소 산화물의 생체내 농도를 감소시키는 방법및 그에 유용한조성물 | |
US5747532A (en) | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor | |
US5922761A (en) | Methods for in vivo reduction of iron levels and compositions useful therefor | |
Komarov et al. | Detection of nitric oxide production in mice by spin-trapping electron paramagnetic resonance spectroscopy | |
AU749755B2 (en) | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide | |
US6469057B1 (en) | Methods for in vivo reduction of free radical levels and compositions useful therefor | |
EP0811380A2 (en) | Use of vanadiumcompositions for lowering blood sugar levels | |
US4952607A (en) | Copper complex for treating cancer | |
US5756540A (en) | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor | |
JP2000506170A (ja) | 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物 | |
US5240914A (en) | Method and compositions for inhibiting tumor cell metabolism | |
US6509380B1 (en) | Method of treating iron overload with acetaminophen | |
Sun et al. | Bismuth antiulcer complexes | |
Chung | Cancer, chemotherapy and anaesthesia | |
DE69829315T2 (de) | Verwendung von chelatbildnern zur behandlung atherosklerotischer beschwerden | |
WO2014189789A1 (en) | Treatment of hypotension associated with hemodialysis | |
JP2727431B2 (ja) | 生体内ラジカル消去剤 | |
US5858402A (en) | Methods for in vivo reduction of cyanide levels and compositions useful therefor | |
CN116710091A (zh) | 用于治疗骨髓增生异常综合征(mds)的膜铁转运蛋白抑制剂 | |
MXPA99001505A (en) | Pharmaceutical compositions comprising tyrphostins | |
Kapoor et al. | Effect of dietary protein on glomerular renin secretion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B90T | Transfer of trial file for re-examination | ||
E902 | Notification of reason for refusal | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20031226 Effective date: 20050729 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050902 Effective date: 20061011 |
|
J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20061106 Effective date: 20090130 |
|
J222 | Remand (patent court) |
Free format text: REMAND (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090210 Effective date: 20090529 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090626 Effective date: 20090821 |
|
S901 | Examination by remand of revocation | ||
E902 | Notification of reason for refusal | ||
S601 | Decision to reject again after remand of revocation |